About Photys Therapeutics
Photys Therapeutics is a company based in Cambridge (United States) founded in 2021. Photys Therapeutics has raised $75 million across 1 funding round from investors including Lilly, Turmeric Acquisition Corp and Mass General Brigham Ventures. Photys Therapeutics offers products and services including PROTAC, tPRIME, and PHICS. Photys Therapeutics operates in a competitive market with competitors including Accutar Biotechnology, Plexium, Lycia Therapeutics, Vicinitas and Uvic Steratics, among others.
- Headquarter Cambridge, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$75 M (USD)
in 1 rounds
-
Latest Funding Round
$75 M (USD), Series A
Sep 08, 2022
-
Investors
Lilly
& 9 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Photys Therapeutics
Photys Therapeutics offers a comprehensive portfolio of products and services, including PROTAC, tPRIME, and PHICS.
Bifunctional molecule that degrades target proteins via ubiquitination
Enhances target protein expression through proximity induction
Induces phosphorylation on specific proteins for modulation
People of Photys Therapeutics
Unlock access to complete
Funding Insights of Photys Therapeutics
Photys Therapeutics has successfully raised a total of $75M through 1 strategic funding round. The most recent funding activity was a Series A round of $75 million completed in September 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Photys Therapeutics
Photys Therapeutics has secured backing from 10 investors, including institutional and venture fund investors. Prominent investors backing the company include Lilly, Turmeric Acquisition Corp and Mass General Brigham Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
Venture capital is directed toward healthcare companies by Longwood Fund.
|
Locked | Locked | Locked | |
|
Venture capital firm
|
Locked | Locked | Locked |
Investor details for Photys Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Photys Therapeutics
Investment portfolio details for Photys Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Photys Therapeutics
Detailed financials for Photys Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Photys Therapeutics Comparisons
Peer comparison for Photys Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Photys Therapeutics
Photys Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Accutar Biotechnology, Plexium, Lycia Therapeutics, Vicinitas and Uvic Steratics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
AI-assisted tools for drug discovery are developed.
|
|
| Locked | Locked | Locked |
Integrated chemistry service provider
|
|
| Locked | Locked | Locked |
Protein degradation drugs are developed for cancer and autoimmune diseases.
|
|
| Locked | Locked | Locked |
Developer of therapeutics for cancer and genetic disorders
|
|
| Locked | Locked | Locked |
Anti-cancer drugs are developed via Proteolysis Targeting Chimera technology.
|
Detailed competitors of Photys Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Photys Therapeutics
Complete news archive for Photys Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Photys Therapeutics
Photys Therapeutics was founded in 2021 and raised its 1st funding round 1 year after it was founded.
Photys Therapeutics is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
David Steinberg is the current CEO of Photys Therapeutics.
Photys Therapeutics is a funded company, having raised a total of $75M across 1 funding round to date.
Photys Therapeutics was founded in 2021 and is based in Cambridge, United States. Operations center on biotechnology, where a proprietary bifunctional small molecules platform is utilized to regulate protein post-translational modifications. This approach aims to restore protein function, repair signaling pathways, and enhance endogenous mechanisms against diseases. A pipeline focused on oncology indications is being advanced through these efforts.
Photys Therapeutics's top competitors include Plexium, Uvic Steratics and Accutar Biotechnology.
Photys Therapeutics offers PROTAC, tPRIME, and PHICS.
Photys Therapeutics has 10 investors. Key investors include Lilly, Turmeric Acquisition Corp, Mass General Brigham Ventures, Longwood Fund, and Omega Funds.